<DOC>
	<DOCNO>NCT00804687</DOCNO>
	<brief_summary>The purpose study evaluate relative efficacy JNJ- 39220675 pseudoephedrine compare placebo ( medication active ingredient ) participant allergic rhinitis ( inflammation nose due exposure allergens pollen , dust animal hair ) .</brief_summary>
	<brief_title>An Efficacy Study JNJ-39220675 Pseudoephedrine Participants With Allergic Rhinitis</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , single-dose , single-blind ( clinical trial person give treatment , participant , know treatment participant receiving ) , double-dummy , placebo-controlled , three-treatment period , cross-over ( participant may receive different intervention sequentially trial ) study JNJ-39220675 participant allergic rhinitis . The duration study 20-64 day per participant . The study consist 2 part : Screening ( , 30 day study commences Day 1 ) Treatment ( consist single-dose either JNJ-39220675 solution [ 10 milligram ] , Pseudoephedrine tablet [ 60 milligram ] Placebo , subsequent three-treatment period , separate washout period 6 day ) . All eligible participant randomly assign 1 6 treatment sequence . Participants give dose approximately 2 hour entry environmental exposure chamber expose ragweed pollen 8 hour . Efficacy primarily evaluate measurement nasal congestion assess nasal cavity geometry , minimal cross-sectional area nasal cavity Acoustic rhinometry . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<criteria>Participants must clinical history seasonal allergic rhinitis seasonal onset offset nasal allergy symptom least last two ragweed allergy season Participants must documentation positive skin test within 12 month Screening ragweed allergen define positive case history positive skin prick and/or intradermal test ( allergy test perform inject allergycausing substance underneath skin see cause reaction ) ragweed allergen Female participant must pregnant , lactate able become pregnant Male participant must consent use medically acceptable method contraception throughout entire study period 3 month study complete Participants body mass index 18 32 kilogram per square meter Participants clinically significant physical finding nasal anatomical deformity Participants history risk factor torsades de pointes ( heart failure , hypokalemia , family history long QT syndrome ) , use concomitant medication prolong QT QTc interval abnormal 12lead electrocardiogram except clinically nonsignificant bradycardia Participants history exposure investigational treatment within 30 day Screening Visit , ever take JNJ39220675 previously Participants history clinically significant allergy , especially know hypersensitivity intolerance drug know allergy study drug excipients formulation Participants history severe respiratory infection disorder , epilepsy seizure , coronary heart disease , uncontrolled hypertension , clinically significant cardiovascular disease , history positive test Human immunodeficiency ( HIV ) , Hepatitis B Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Rhinitis</keyword>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>JNJ-39220675</keyword>
	<keyword>Pseudoephedrine</keyword>
</DOC>